- Home
- IMUX vs DTIL Comparison
IMUX vs DTIL Comparison
Compare IMUX & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- DTIL
- Stock Information
- Founded
- IMUX 2016
- DTIL 2006
- Country
- IMUX United States
- DTIL United States
- Employees
- IMUX N/A
- DTIL 67
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- DTIL Health Care
- Exchange
- IMUX Nasdaq
- DTIL Nasdaq
- Market Cap
- IMUX 92.2M
- DTIL 81.4M
- IPO Year
- IMUX N/A
- DTIL 2019
- Fundamental
- Price
- IMUX $0.72
- DTIL $6.14
- Analyst Decision
- IMUX Strong Buy
- DTIL Strong Buy
- Analyst Count
- IMUX 5
- DTIL 2
- Target Price
- IMUX $7.00
- DTIL $47.00
- AVG Volume (30 Days)
- IMUX 1.4M
- DTIL 188.6K
- Earning Date
- IMUX 11-06-2025
- DTIL 11-03-2025
- Dividend Yield
- IMUX N/A
- DTIL N/A
- EPS Growth
- IMUX N/A
- DTIL N/A
- EPS
- IMUX N/A
- DTIL N/A
- Revenue
- IMUX N/A
- DTIL $698,000.00
- Revenue This Year
- IMUX N/A
- DTIL N/A
- Revenue Next Year
- IMUX N/A
- DTIL $135.19
- P/E Ratio
- IMUX N/A
- DTIL N/A
- Revenue Growth
- IMUX N/A
- DTIL N/A
- 52 Week Low
- IMUX $0.56
- DTIL $3.61
- 52 Week High
- IMUX $1.42
- DTIL $8.82
- Technical
- Relative Strength Index (RSI)
- IMUX 37.43
- DTIL 43.74
- Support Level
- IMUX $0.67
- DTIL $6.18
- Resistance Level
- IMUX $0.87
- DTIL $8.77
- Average True Range (ATR)
- IMUX 0.05
- DTIL 0.66
- MACD
- IMUX -0.01
- DTIL -0.21
- Stochastic Oscillator
- IMUX 21.92
- DTIL 3.64
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.